Curespec is ushering in a new era of hope for chronic kidney disease (CKD) and hypertensive patients with Nephrospec™, our cutting-edge technology.
We stand as pioneers, offering a life-extending treatment that revitalizes kidneys, delays the need for dialysis, and lowers blood pressure, all while making significant cost savings for healthcare systems.
Nephrospec™ is a safe, non-invasive low intensity electro-Hydraulic Acoustic Therapy device for the treatment of CKD and hypertension.
Our patented technology promotes new blood vessel formation and restores damaged tissue function while saving up to 80% of the costs associated with dialysis.
Nephrospec™ by Curespec:
A complementary solution to optimize medical care for CKD and hypertension
Improvement of kidney function within a few weeks
Delayed onset of outpatient treatment for dialysis
Post Shockwave treatment
Curespec uses shockwave technology to produce a neovascularization affect on the kidneys.
Founder, Active Chairman
Mr. Spector has over 30 years experience in the international Medtech industry, having held top R&D management positions in medical instrument companies in Israel and the US. He holds a B.Sc. Degree in Mechanical Engineering from Ben-Gurion-University of the Negev, Israel.
Ms. Morgan has over 32 years in healthcare with Fortune 100 companies including HCA Healthcare and Pfizer. In the past she was an executive at HCA Healthcare responsible for business growth through physicians and service lines. In her last role at Pfizer, Sandra led the US managed care team responsible for achieving formulary status for Pfizer’s portfolio.